|
Exhibit 10.50
Confidential Materials omitted and filed
separately with the
Securities and Exchange Commission. Asterisks
denote omissions.
SECOND AMENDMENT TO LICENSE, SUPPLY AND
DISTRIBUTION AGREEMENT
THIS SECOND AMENDMENT TO LICENSE, SUPPLY AND DISTRIBUTION
AGREEMENT is made and entered into as of this 24th day of October,
2006 (Effective Date) by and between F.Hoffmann-La Roche Ltd.
("FHLR") having a principal office at Grenzacherstrasse 124, Basel,
Switzerland and 454 Life Sciences Corporation ("454") having a
principal office at 20 Commercial Street, Branford, CT 06405,
USA.
RECITALS
WHEREAS, the Parties have entered into a written License, Supply
and Distribution Agreement dated May 11, 2005, as amended by
the First Amendment to License, Supply and Distribution Agreement
dated December 19, 2005 ("Original Agreement"); and
WHEREAS, the Parties intend to launch Rev. 1.1 (under the
product name GS FLX) now a Proposed Licensed Product listed under
Exhibit 5 of the Original Agreement. Customers who bought the Rev.
1.0 (the product name being GS 20) will have the choice to upgrade
their Rev 1.0 instrument to a Rev. 1.1 instrument. Hereby, the
Parties wish to agree on the sharing of costs for such an
upgrade.
NOW THEREFORE, in consideration of the covenants and
mutual promises set forth herein, the receipt and sufficiency of
which are hereby acknowledged, the Parties agree as follows:
1. The following new Section 3.3 (e) shall be added
to the Original Agreement:
"454 shall charge FHLR, and FHLR will purchase from 454 an
upgrade for the Rev. 1.0 ("Upgrade") at a transfer price of [**]
percent ([**] %) for each of the Upgrades based on the
estimated Average Unit Upgrade Price ("AUUP"). The AUUP
shall be the total amount invoiced to customers for Upgrades
divided by the total number of Upgrades. The initial
estimated AUUP for the Upgrade shall be [**] US Dollars (US
$ [**]). The value of the estimated AUUP shall be subject to
adjustment based on the actual AUUP. The calculation of the
actual AUUP shall be done in the same way as for the ASP in
Section 3.3 (c) of the Original Agreement.
Furthermore, FHLR will pay 454 a fixed amount of [**] percent
([**] %) of the material costs for every upgrade of a Rev. 1.0
which consists of the delivery according to Specifications of a
Rev. 1.1 instrument [**]. The material costs for an Upgrade are
currently [**] US Dollars (US $ [**]). In the event 454 does the
Upgrade, FHLR shall also reimburse 454’s actual costs for
(i) travel of 454 personnel to upgrade Rev. 1.0 instruments
(ii) personnel costs for the installation in the amount of
$[**] per day of installation. These costs are the total costs of
454 for upgrading a Rev. 1.0 to a Rev. 1.1 at the customer’s
site. If FHLR does the Upgrade with its own technical service
personnel, FHLR shall not be obligated to pay 454 costs for travel
and installation.
Based on its 2006 forecast, FHLR has so far failed to order [**]
Rev. 1.0 instruments from 454. Instead of purchasing those
remaining Rev. 1.0 instruments, FHLR shall have the option to pay
454 a compensation of [**] US Dollars (US $ [**]) per Rev. 1.0
instrument by December 31,
2006. This shall be 454’s sole remedy for
FHLR not taking delivery of the instruments. FHLR will inform 454
the latest by October 31, 2006 about the number of Rev 1.0
instruments (if any) which it will order before December 31,
2006, with any unordered balance of the 2006 forecast subject to
the above payment.
If FHLR has by the end of the calendar year 2006 any Rev. 1.0
instruments in stock and FHLR chooses to upgrade those instruments,
FHLR shall only pay the material costs of [**] US Dollars (US $
[**]) for such Upgrade without further payments. Such payment will
not be deducted from any customer receipts for calculation of the
ASP (Section 3.3) or royalties (Section 3.4) for the Rev. 1.1
instrument."
2. The following new Section 3.4 (a)(vii) shall be added
to the Original Agreement:
"[**] percent ([**] %) on Net Sales of Upgrades."
3 . The Upgrade will be done on the basis of the
following specifications (Exhibit 16):
(See attached document.)
4 . Exhibit 3 shall be complemented according to
Section 2.7 of the Original Agreement by addition of the
Specifications for the Rev. 1.1 instrument as follows:
[**]
5. According to Section 3.3 (b) of the Original
Agreement the Parties hereby amend Exhibit 2 by adding the
following for the additional Licensed Products Rev. 1.1, emPCR Kits
II, III and paired end adaptor kit:
(See attached documents.)
6. The Parties agree to amend the Original Agreement such
that the text of Exhibit 5, "Proposed Licensed Products, Launch
Dates and Initial Estimated ASP" shall be deleted in its entirety
and replaced with the following:
(See attached document.)
7. Both new GS FLX instruments and upgraded Rev. 1.0
(GS20) instruments are warranted by 454 to FHLR for [**] starting
with installation of the GS FLX instruments at the customer and
with completion and installation at the customer of the upgrade for
the Rev. 1.0 (GS20) instruments. This warranty is extended by FHLR
or its Affiliates to the customer.
IN WITNESS WHEREOF, each of the Parties
has caused this Second Amendment to the Original Agreement to be
executed by its duly authorized representative.
| |
|
|
|
|
|
|
|
|
|
Basel,
|
|
|
|
Branford,
|
|
F. Hoffmann-La Roche Ltd
|
|
|
|
454 Life Sciences
|
|
|
|
|
|
|
B
|
|